BridgeMD
New treatment option for Insulin Sensitivity
Official title mTOR as Mediator of Insulin Sensitivity Study
ClinicalTrials.gov ID: NCT05233722
What this study is testing
What is Rapamycin?
Rapamycin is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for insulin sensitivity.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise. This will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 22 to 35, men only. Healthy volunteers may be eligible.
You may be able to join if
- Healthy persons (no known disease) without diabetes in the family
- No use of medications
- Non-smokers
- Age 22-35 years
- Physical activity level (VO2peak) between 30-50 mL O2/min/kg
You likely can't join if
- Women
- Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week.
- Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid...
- Acute sickness less than 2 weeks prior to study start.
- If disease appears or is identified and/or a need for medication arises after inclusion but before initiation of the study. Disease during conclusion...
See the full eligibility criteria
- Healthy persons (no known disease) without diabetes in the family
- No use of medications
- Non-smokers
- Age 22-35 years
- Physical activity level (VO2peak) between 30-50 mL O2/min/kg
- BMI between 18.0 and 25.0
- Women
- Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week.
- Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid diseases or other signs of disease that may affect the outcome of the...
- Acute sickness less than 2 weeks prior to study start.
- If disease appears or is identified and/or a need for medication arises after inclusion but before initiation of the study. Disease during conclusion of the study
The study team makes the final eligibility decision.
Where it's taking place
- Copenhagen, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 22 years to 35 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Copenhagen, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.